Gout in the Hmong in the United States.
OBJECTIVE
To compare characteristics of gout in Hmong patients versus whites, and examine if Hmong ethnicity is associated with risk of tophaceous gout.


METHODS
A retrospective chart review of Hmong and White patients with gout in a large health care system (Health Partners) in St. Paul, Minnesota, from January 2001 to March 2008, to compare clinical characteristics and risk factors for gout. Multivariable-adjusted hierarchical logistic regressions examined the association of Hmong ethnicity with risk of tophaceous gout, adjusting for age, sex, hypertension, diuretic use, and kidney function.


RESULTS
The analytic dataset consisted of 89 Hmong patients and 84 White controls, all of whom had ethnicity confirmed, an International Classification of Diseases, ninth revision code for gout and had at least 2 physician-documented diagnoses of gout. The Hmong group was younger (58.3 vs. 66.3 years, P = 0.04), had an earlier onset of symptoms (37.4 vs. 55.0 years, P < 0.001) and higher mean serum uric acid levels during follow-up (9.1 vs. 7.6 mg/dL, P < or = 0.001). Hmong had higher rates of tophaceous gout (31.5% vs. 10.7%, P = 0.001), including hand tophi (21.3% vs. 3.6%, P < 0.001). In multivariable analyses that adjusted for age, sex, hypertension, diuretic, use, and kidney function, Hmong ethnicity was significantly associated with risk of tophaceous gout, with odds ratio 4.3 (95% confidence interval: 1.5, 12.2).


CONCLUSIONS
Hmong patients have an earlier onset of gout symptoms. Hmong race is an independent risk factor for tophaceous gout. Future studies need to examine whether genetic or other comorbid factors predict this higher risk of more severe gout in Hmong.
Wahedduddin
Salman
S
Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, USA.
Singh
Jasvinder A
JA
Culhane-Pera
Kathleen A
KA
Gertner
Elie
E
D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D001213:Asian / Q000208:ethnology*; D005260:Female; D006073:Gout / Q000188:drug therapy / Q000453:epidemiology* / Q000208:ethnology*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology; D044465:White People / Q000208:ethnology
D006074:Gout Suppressants; D000493:Allopurinol
Am J Hum Genet. 2004 Sep;75(3):498-503
15252757
N Engl J Med. 2004 Mar 11;350(11):1093-103
15014182
Br J Rheumatol. 1984 Nov;23(4):276-82
6487933
J Endourol. 2004 Nov;18(9):853-7
15659918
WMJ. 2005 Jul;104(5):70-7
16138520
J Clin Rheumatol. 2009 Feb;15(1):22-4
19125136
Arthritis Rheum. 2004 Jan;50(1):242-6
14730622
J Am Diet Assoc. 2007 Jun;107(6):936-41
17524713
J Rheumatol. 2006 Sep;33(9):1813-7
16960942
Arthritis Rheum. 2004 Dec 15;51(6):952-7
15593102
J Rheumatol. 2003 Nov;30(11):2437-43
14677190
N Z Med J. 2008 May 23;121(1274):79-85
18535649
Arthritis Rheum. 2007 Feb 15;57(1):103-8
17266097
Arthritis Rheum. 2007 Jun 15;57(5):822-9
17530682
Cancer Causes Control. 1997 Sep;8(5):705-12
9328192
J Rheumatol. 1999 Aug;26(8):1802-7
10451080
Rheumatology (Oxford). 2007 Dec;46(12):1804-7
17982165
Arthritis Rheum. 1977 Apr;20(3):895-900
856219
Mol Biol Evol. 2005 Mar;22(3):725-34
15548747
Br J Rheumatol. 1998 Mar;37(3):258-62
9566664
Arthritis Rheum. 2007 May 15;57(4):648-55
17471541
Am J Phys Anthropol. 2007 Dec;134(4):481-8
17668442